The PD‐1 Interactome
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
T cell activation is a fine-tuned process that involves T cell receptor and costimulation signals. To prevent undue activation of T cells, inhibitory molecules including PD-1 (programmed death 1) are induced and function as brakes for T cell signaling. In a steady state, the interaction of PD-1 with its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273) maintains peripheral immune tolerance. However, the expression of PD-L1 on tumor cells and interaction with PD-1 on T cells dampen anti-tumor immunity. Therapeutic inhibitors of the PD-1 pathway have revolutionized tumor immunotherapy. Unfortunately, the majority of patients do not develop sustained anti-tumor responses. However, the knowledge about unique PD-1 interactions and their role in mediating PD-1 inhibitory signals is currently limited. Advances in the mechanistic understanding of the molecular and signaling integration of the PD-1 pathway could unleash the great potential in tumor immunotherapy by allowing the development of combinatorial approaches that target not only PD-1 and its ligands but also its unique downstream signal mediators. In this review, the current advances in understanding the mechanisms of extracellular and intracellular PD-1 interactions and their significance in potential future therapeutic approaches are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies showed quantitatively applied mass spectrometry of PD‐1 signalosome assembly in primary effector T cells and confirmed that PD‐1 mainly recruited SHP2 [282, 287, 288].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [288]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Regulation and Function of the PD-L1 Checkpoint
Sun, C., Mezzadra, R., & Schumacher, T. N. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.014 · Cited by 2,193
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
Research works printed but not linked: 1
- 10.1093/intimm/8.5.765 · DOI · Paper page
Cited by
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Salminen, A. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-024-02444-6 · Cited by 67
Tumor-Associated Macrophages: Key Players in Triple-Negative Breast Cancer
Qiu, X., Zhao, T., Luo, R., Qiu, R., & Li, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.772615 · Cited by 63
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 66
Rajasekaran, N., Wang, X., Ravindranathan, S., Chin, D. J., Tseng, S.-Y., Klakamp, S. L., Widmann, K., Kapoor, V. N., Vexler, V. S., Keegan, P., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03635-3 · Cited by 39
PD-1/LAG-3 bispecific antibody potentiates T cell activation and increases antitumor efficacy
Shi, N., Zhou, Y., Liu, Y., Zhang, R., Jiang, X., Ren, C., Gao, X., & Luo, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1047610 · Cited by 43
Engineered biological nanoparticles as nanotherapeutics for tumor immunomodulation
Rahmat, J. N., Liu, J., Chen, T., Li, Z., & Zhang, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00602f · Cited by 45
Immunomodulatory Properties of Immune Checkpoint Inhibitors—More than Boosting T-Cell Responses?
Kuske, M., Haist, M., Jung, T., Grabbe, S., & Bros, M. (2022) · Cancers · doi:10.3390/cancers14071710 · Cited by 39
Effects of PD-1 Signaling on Immunometabolic Reprogramming
Boussiotis, V. A., & Patsoukis, N. (2022) · Immunometabolism · doi:10.20900/immunometab20220007 · Cited by 41
Self-citationCombination Approaches to Target PD-1 Signaling in Cancer
Moore, E. K., Strazza, M., & Mor, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.927265 · Cited by 34
Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma
Nanamori, H., & Sawada, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031119 · Cited by 29
Mismatch Repair Deficiency and Microsatellite Instability
Schöniger, S., & Rüschoff, J. (2022) · Encyclopedia · doi:10.3390/encyclopedia2030106 · Cited by 29
Lemaître, F., Farzam‐kia, N., Moratalla, A. C., Solorio, Y. C., Clénet, M., Tastet, O., Cleret‐Buhot, A., Guimond, J. V., Haddad, É., Duquette, P., et al. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02572-1 · Cited by 21
Navigating the landscape of PD-1/PD-L1 imaging tracers: from challenges to opportunities
Badenhorst, M., Windhorst, A. D., & Beaino, W. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1401515 · Cited by 20
Mucherino, S., Lorenzoni, V., Triulzi, I., Re, M. D., Orlando, V., Capuano, A., Danesi, R., Turchetti, G., & Menditto, E. (2024) · Cancers · doi:10.3390/cancers16050995 · Cited by 21
Ye, W., Wu, Z., Gao, P., Kang, J., Xu, Y. M., Wei, C., Zhang, M., & Zhu, X. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939021 · Cited by 18
The PD-1/PD-L1 Pathway: A Perspective on Comparative Immuno-Oncology
Schöniger, S., & Jasani, B. (2022) · Animals · doi:10.3390/ani12192661 · Cited by 24
Mor, A., & Strazza, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.790386 · Cited by 17
Proschinger, S., Schenk, A., Weßels, I., Donath, L., Rappelt, L., Metcalfe, A. J., & Zimmer, P. (2023) · European Journal of Applied Physiology · doi:10.1007/s00421-023-05251-y · Cited by 17
The Mechanisms of Ferroptosis and the Applications in Tumor Treatment: Enemies or Friends?
Tan, S., Kong, Y., Xian, Y., Gao, P., Xu, Y., Wei, C., Lin, P., Ye, W., Li, Z., & Zhu, X. M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.938677 · Cited by 14
Engineered PD-L1 nanoregulators for enhanced tumor immunotherapy
Inam, M., Ren, K., Shen, B., Zhou, F., Tian, L., Liu, J., & Sun, X. J. (2025) · Biomaterials Science · doi:10.1039/d5bm00748h · Cited by 12
Dimerization of Transmembrane Proteins in Cancer Immunotherapy
Li, L., & Li, J. (2023) · Membranes · doi:10.3390/membranes13040393 · Cited by 12
The mechanisms and effects of lactylation modification in different kinds of cancers
Sun, Y., Yang, X., Kong, F., Dong, F. Y., Li, N., & Wang, S. (2025) · Discover Oncology · doi:10.1007/s12672-025-02359-9 · Cited by 12
BTLA and PD-1 signals attenuate TCR-mediated transcriptomic changes
Arifin, M. Z., Leitner, J. M., Egan, D., Waidhofer‐Söllner, P., Kölch, W., Zhernovkov, V., & Steinberger, P. (2024) · iScience · doi:10.1016/j.isci.2024.110253 · Cited by 7
Al-nakhle, H. H., Al-Shahrani, R., Al-Ahmadi, J., Al-Madani, W., & Al-Juhani, R. (2025) · Genes · doi:10.3390/genes16030307 · Cited by 6
Exclusion of PD-1 from the immune synapse: A novel strategy to modulate T cell function
Hao, L. Y., Lerrer, S., Paiola, M., Moore, E. K., Gartshteyn, Y., Song, R., Goeckeritz, M., Black, M. J., Bukhari, S., Hu, X., et al. (2024) · Molecular Therapy Oncology · doi:10.1016/j.omton.2024.200839 · Cited by 6
High TOX expression on CD8+ T cells in pure red cell aplasia
Niu, H., Li, Y., Yang, L., Zhang, M., Liu, M., Ren, J., Shao, Z., Fu, R., Xing, L., & Wang, H. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05174-w · Cited by 6
Singh, S., Yadav, J., Singh, S., Sahu, S. K., Puneet, P., & Singh, R. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00326-4 · Cited by 3
Li, Z.-H., Wang, Y., Zuo, C. R., Men, J.-S., Li, X., Luo, P., Su, X., & Sun, R. (2025) · BMC Cancer · doi:10.1186/s12885-025-14264-z · Cited by 4
Altıntaş, I., Nuermberger, K., Imle, A., Krause, A.-L., van Beuge, M. M., Toker, A., Ioan‐Facsinay, A., Blum, J. M., Muik, A., Beurskens, F. J. M., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11990-z · Cited by 2
Ratka, Z., Gamian, A., & Woźniak, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27114923 · Cited by 2
Polymeric micelles as delivery systems for anticancer immunotherapy
Parayath, N. N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89868-3.00004-5
Hashemipour, Y., Jahantigh, D., Forghani, F., Zidanloo, S. G., Zamen, B., & Rezaei, M. (2025) · Bratislavské lekárske listy/Bratislava medical journal · doi:10.1007/s44411-025-00463-4
袁, 玺. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.162566
Dostarlimab in the Treatment of Endometrial Cancer: An Overview
Ghimiray, P., Meghna, G. R., & Ramakrishnan, A. V. P. (2026) · Clinical Cancer Drugs · doi:10.2174/012212697x393690251202115048
Yan, S., Zhang, G., & Jia, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1832333
Recent Developments in Macrophages Imbalance and Recurrent Spontaneous Abortion
Xiao, Y., Zeng, F.-Y., Liu, J.-S., Zhao, F., & Sun, J.-L. (2026) · Journal of Immunology Research · doi:10.1155/jimr/8862057
Botchkova, E., Churov, A. V., & Arbatskiy, M. S. (2026) · Immuno · doi:10.3390/immuno6030049
To Be or Not to Be—Thymocyte Survival and Death in the Thymic Medulla
Zúñiga, M. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209078
Metadata
- Authors
- Wang, Q., Bardhan, K., Boussiotis, V. A., & Patsoukis, N.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Boussiotis, Vassiliki A.
- Patsoukis, Nikolaos
- Venue
- Advanced Biology
- Publisher
- Wiley
- Published
- 2021-06-25
- Volume
- 5
- Issue
- 9
- Pages
- e2100758-e2100758
- ISSN
- 2701-0198 (ISSN-L)
- PMC
- PMC10754315
- OpenAlex
- W3174507556
- Cited by
- 39
- References
- 65
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 5 · 2022: 13
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Advanced Biology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-nd)
- Funders
- National Institutes of Health (R01CA238263, R01CA212605, R01CA229784, R21AR073494)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Keywords
- PD-1, PD-L1, PD-L2, T cell activation, immune checkpoint, cancer immunotherapy, PD-1 inhibitors, PD-1 signaling, peripheral tolerance, T cell receptor signaling, combination immunotherapy
- MeSH terms
- Humans, Immunotherapy, Ligands, Lymphocyte Activation, T-Lymphocytes, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.